Physician profile

Saagar Seth

Riverside, CA

NPI 1770112773

$405.72

in general payments reported to CMS, 2019-2025

7 companies · $281 in 2025

The $281 reported for 2025 was more than what a typical provider received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$405.72

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $149.21 2025 Botox, Qulipta, Ubrelvy
Sk Life Science, INC. $124.97 2024 Xcopri
Biogen, INC. $38.54 2025 Leqembi
Forte Bio-Pharma LLC $26.75 2025 Tanlor
Novartis Pharmaceuticals Corporation $24.46 2025
Amneal Pharmaceuticals LLC $23.08 2025 Crexont
Livanova USA, INC. $18.71 2025 Vns Therapy

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Saagar Seth

$405.72

in general payments reported 2019-2025

Years
2024-2025
Top company
Abbvie INC.
Context
The $281 reported for 2025 was more than what a typical provider received nationally.

https://glasscript.com/doctor/11703379/saagar-seth

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.